BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trastuzumab brengitecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trastuzumab brengitecan\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05631964-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab brengitecan: Phase 1 readout est. (NCT05631964)
DESCRIPTION:Trastuzumab brengitecan\, phase 1.\nStudy: Phase I Clinical Stu
 dy of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors an
 d Other Solid Tumors\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-brengitecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05631964
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05461768-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab brengitecan: Phase 1 readout est. (NCT05461768)
DESCRIPTION:Trastuzumab brengitecan\, phase 1.\nStudy: A Study of BL-M07D1 
 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Bre
 ast Cancer and Other Solid Tumors\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-bre
 ngitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05461768
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031584-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab brengitecan: Phase 1/2 readout est. (NCT06031584)
DESCRIPTION:Trastuzumab brengitecan\, phase 1/2.\nStudy: A Study of BL-M07D
 1 in Patients With a Variety of Solid Tumors Including Locally Advanced or
  Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumo
 rs\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06031584
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06114511-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab brengitecan: Phase 1/2 readout est. (NCT06114511)
DESCRIPTION:Trastuzumab brengitecan\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER
 2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer\nEstima
 ted primary completion: December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06114511
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06131450-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Trastuzumab brengitecan: Phase 1/2 readout est. (NCT06131450)
DESCRIPTION:Trastuzumab brengitecan\, phase 1/2.\nStudy: A Study of BL-M07D
 1 in Patients With Recurrent or Metastatic Gynecologic Malignancies\nEstim
 ated primary completion: January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06131450
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06957886-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT06957886)
DESCRIPTION:Trastuzumab brengitecan\, phase 3.\nStudy: A Study of BL-M07D1 
 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Rec
 urrent/Metastatic Breast Cancer\nEstimated primary completion: May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-brengiteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 957886
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152405-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07152405)
DESCRIPTION:Trastuzumab brengitecan\, phase 3.\nStudy: A Study of BL-M07D1 
 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positiv
 e Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Ade
 nocarcinoma\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07152405
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264816-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 2 readout est. (NCT07264816)
DESCRIPTION:Trastuzumab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-M07D1 in Combination With Pembrolizumab in Patients
  With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-
 Squamous NSCLC\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07264816
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178795-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07178795)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in Fir
 st-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07178795
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730489-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07730489)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Colorectal Cancer.\nStudy: 
 A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients Wit
 h HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Ox
 aliplatin\, Fluorouracil and Irinotecan\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzum
 ab-brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07730489
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678957-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 2 readout est. (NCT07678957)
DESCRIPTION:Trastuzumab brengitecan\, phase 2.\nStudy: A Study Comparing BL
 -M07D1 With DS-8201 in Patients With HR-Positive\, HER2-Low Expressing Rec
 urrent/Metastatic Breast Cancer\nEstimated primary completion: December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-breng
 itecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07678957
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891833-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 2/3 readout est. (NCT06891833)
DESCRIPTION:Trastuzumab brengitecan\, phase 2/3\, HER2-Positive Breast Canc
 er.\nStudy: A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxe
 l + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2
 -Positive Breast Cancer\nEstimated primary completion: December 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-brengitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06891
 833
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545460-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07545460)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patient
 s With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Can
 cer\, Fallopian Tube Cancer\, and Primary Peritoneal Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07545460
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07606599-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07606599)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Biliary Tract Cancer.\nStud
 y: A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patien
 ts With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cance
 r After Platinum-containing Chemotherapy Failure\nEstimated primary comple
 tion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-brengitecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07606599
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07869836-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07869836)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Urothelial Carcinoma.\nStud
 y: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-
 based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer 
 After Progression on Anti-PD-(L)1-based Therapy\nEstimated primary complet
 ion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 rastuzumab-brengitecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07869836
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06293898-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Trastuzumab brengitecan: Phase 1 readout est. (NCT06293898)
DESCRIPTION:Trastuzumab brengitecan\, phase 1\, Ovarian Cancer.\nStudy: Ope
 n Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumo
 rs\nEstimated primary completion: 15 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06293898
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518173-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07518173)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, HER2-Positive Breast Cancer
 .\nStudy: A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Pl
 us Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Re
 current or Metastatic Breast Cancer\nEstimated primary completion: Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-b
 rengitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07518173
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830889-2282@assetmemo.bio
DTSTAMP:20261121T005723Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT06830889)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, HER2-Positive Breast Cancer
 .\nStudy: A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HE
 R2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant 
 Therapy\nEstimated primary completion: October 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06830889
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
